The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients

The Hematology Journal : the Official Journal of the European Haematology Association
P DregerR Haas

Abstract

The purpose of this analysis was to investigate if early sequential high-dose therapy with autologous stem cell transplantation (ASCT) can improve the poor prognosis of patients with disseminated mantle cell lymphoma (MCL). A joint analysis of two parallel single center studies was performed. Both were characterized by a sequential high-dose therapy consisting of an intensive chemotherapy ('HAM' or 'Dexa-BEAM') for mobilization of peripheral blood stem cells and induction of minimal disease followed by a total body irradiation-containing myeloablative regimen and ASCT. Forty-six patients with reference panel-confirmed stage III/IV MCL were included. Thirty-four patients were accrued to the protocol immediately after diagnosis ('upfront ASCT' group). These 34 patients received a standard first-line regimen prior to mobilization. The remaining 12 patients were put on the protocol later during the course of their disease ('delayed ASCT' group). All patients were in remission after mobilization chemotherapy and proceeded to ASCT; there were no exclusions due to poor response, poor mobilization, or patient refusal. With a follow-up of 24 (2-73) months post transplant, the event-free and overall survival probabilities at 2 years were...Continue Reading

Citations

Feb 20, 2007·Der Internist·M DreylingW Hiddemann
Apr 15, 2008·Future Oncology·K Stephen Suh, Andre Goy
Feb 3, 2007·Current Opinion in Oncology·Yvette L Kasamon
Nov 7, 2002·European Journal of Nuclear Medicine and Molecular Imaging·Christoph von Schilling
Jul 12, 2005·Bone Marrow Transplantation·T L KissJ H Lipton
Feb 26, 2008·Leukemia & Lymphoma·Saar Gill, David Ritchie
Sep 18, 2008·Leukemia & Lymphoma·Lieselot BrepoelsChristiane De Wolf-Peeters
Dec 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter MartinJohn P Leonard
Oct 30, 2009·Leukemia & Lymphoma·Oliver WeigertMartin Dreyling

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.